Novartis Ag (NVSEF) Capital Expenditures (2009 - 2026)

Novartis Ag has disclosed Capital Expenditures across 16 years of filings, most recently posting -$346.0 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at -$346.0 million, down 36.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 17.73% YoY), and the FY2025 annual result was $1.5 billion, up 13.32% from the prior year.
• Capital Expenditures came in at -$346.0 million for Q1 2026 at Novartis Ag, up from -$609.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$168.0 million in Q1 2023 to a low of -$609.0 million in Q4 2025.
• The 5-year median for Capital Expenditures is -$261.0 million (2023), against an average of -$315.4 million.
• Across the five-year window, Capital Expenditures soared 37.04% in 2022 and plunged 37.44% in 2024, its largest moves.
• Novartis Ag's Capital Expenditures stood at -$306.0 million in 2022, then plunged by 32.68% to -$406.0 million in 2023, then slumped by 37.44% to -$558.0 million in 2024, then slipped by 9.14% to -$609.0 million in 2025, then soared by 43.19% to -$346.0 million in 2026.
• The last three Capital Expenditures figures came in at -$346.0 million (Q1 2026), -$609.0 million (Q4 2025), and -$354.0 million (Q3 2025), per Business Quant data.